Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes

What Was Tested

The paper reports a study of Tirzepatide and GIP (Gastric Inhibitory Polypeptide), published as a randomized controlled trial.

To determine the effect of tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptors, on biomarkers of nonalcoholic steatohepatitis (NASH) and fibrosis in patients with type 2 diabetes mellitus (T2DM).

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized and placebo-controlled.

The participants were allocated by chance, so the Tirzepatide group and the comparison group should start out alike.

The comparison arm used a placebo, so changes seen with Tirzepatide could be set against what happens without it.

Changes from baseline in alanine aminotransferase (ALT), aspartate aminotransferase (AST), keratin-18 (K-18), procollagen III (Pro-C3), and adiponectin were analyzed in a modified intention-to-treat population.

What Was Measured

The subject headings attached to it are Alanine Transaminase, Aspartate Aminotransferases, Biomarkers, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Glucagon-Like Peptides and Immunoglobulin Fc Fragments.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Tirzepatide and GIP (Gastric Inhibitory Polypeptide).

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2020 (Diabetes care), a journal based in United States.

More context: the Tirzepatide compound page and the GIP (Gastric Inhibitory Polypeptide) compound page, all human trials.